Subscribe Now Subscribe Today
Science Alert
 
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2008 | Volume: 4 | Issue: 6 | Page No.: 443-451
DOI: 10.3923/ijp.2008.443.451
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Preclinical Evaluation of PM 701 in Experimental Animals

F. Khorshid

Abstract:
In this study, we addressed the toxicological effect of PM 701 on various animal species. Results showed that there was no mortality recorded to doses up to 10 g kg-1 body weights during the 4 weeks of observation. Function tests for Liver (SGOT-SGPT-Alk.Phos) and kidney (urea and creatinine) revealed that PM 701 have no hepatotoxic or nephrotoxic effects. No hematological toxicity was detected. Histological studies, showed no effect on gastric mucosa, no alteration in liver or kidney parenchyamatous architecture. Hepatocytes showed preserved cellular outline with no signs of necrosis. Few renal tubules showed degenerative changes. Splenic tissue showed activation and enlargement of germinal centers of white pulp lymph nodules indicating activation of immune defense without any effect on vital body organs. Therefore, compared to toxicity induced by well known chemotherapeutic agent, PM 701 could be considered safe as potentially anticancer agent with minimal or even negligible effects on vital organs such as liver and kidney and recommended to be subjected to clinical trial in human volunteers. PM 701 was categorized as practically non toxic.
PDF Fulltext XML References Citation Report Citation
 RELATED ARTICLES:
  •    An Analysis of Animal Health and Veterinary Facilities in Coping the Climate Change in Bangladesh: What Education System can Offer for the Benefit
  •    The Impacts of Climate Change on Public Health: Exploring the Link to Pharmacological Knowledge and Education
  •    The Impacts of Climate Change on Animal Health and Economy: A Way Forward for Policy Option
How to cite this article:

F. Khorshid , 2008. Preclinical Evaluation of PM 701 in Experimental Animals. International Journal of Pharmacology, 4: 443-451.

DOI: 10.3923/ijp.2008.443.451

URL: https://scialert.net/abstract/?doi=ijp.2008.443.451

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

Curve Bottom